<DOC>
	<DOCNO>NCT02249403</DOCNO>
	<brief_summary>The objective trial assess dose-response relationship symptomatic efficacy talsaclidine base ADAScog ass safety tolerability</brief_summary>
	<brief_title>Efficacy Safety Talsaclidine Patients With Mild Moderate Dementia Alzheimer Type</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Male female patient , age : 40 year ( low age genetic Dementia Alzheimer Type ( DAT ) document . Patients 85 year need clinically stable state ( investigator 's judgement ) Patient 's educational level &gt; 4 year Patient able understand patient information give inform consent Patient give write informed consent accordance Good Clinical Practice local legislation Patient nondemented relative care giver willing support clinical trial ; his/her write informed consent optional Body weight : within +/ 30 % normal weight ( Broca index ) Diagnosis DAT National Institute Neurological communicative DisordersAlzheimer 's Disease Related Disorder Association ( NINCDSADRDA ) criteria MMSscore 10 24 inclusive Rosen ischemia score lower equal two Patient able complete trial examination , hear , speak , read write basic way primary sensorial function intact Any dementia vascular genesis ( exclude Rosen ischemia score &gt; 2 ) Magnetic Resonance Imaging ( MRI ) Computer Tomogram ( CT ) ( recent 12 month ; MRI CT record perform 12 month study entry , must repeat ) finding make diagnosis DAT unlikely Any stroke history All secondary dementia ( exclusion diagnosis define NINCDSADRDA criterion ) late complication : Craniocerebral trauma Intoxication ( incl . history alcohol drug abuse ) Cerebral infection ( e.g . neurosyphilis ) Thyroid dysfunction Cerebral dysfunction due metabolic disorder ( e.g . unstable thyroid dysfunction , unstable insulindependent diabetes mellitus hypo/hyperglycemic episode ) Deficiency vitamin B12 folic acid reason dementia Brain tumour ( A patient incidental tumour find CT felt clinically relevant may include , i.e . : meningioma ) Down 's syndrome , Parkinsonism , Huntington 's chorea Multiple sclerosis Major depression define Hamilton Depression Rating Scale ( HAMD ) 17 item scale ( ≥ 16 ) Depressive pseudo dementia Mental retardation Hydrocephalus Epilepsy Endogenous psychosis ( schizophrenia ) Untreated noncompensated hypertension ( Blood Pressure systolic &gt; 180 and/or diastolic &gt; 110 mmHg ) Hypertension treat reserpine , clonidine βblockers ( case adjust therapy e.g . calcium antagonists 4 week start treatment ) Severe heart failure ( NYHA : III IV ) Arrhythmias ( Lown : IIIV , Electrocardiogram &gt; 30 ventricular extrasystoles/hour , multifocal multiform repetitive form ventricular extrasystole ) Bronchial asthma phase exacerbation inducible aspirin Nonsteroidal antiinflammatory drug Severe diabetes mellitus : insulin dependent stabilise ( patient HbA1c normal range , clinically stable diabetes case insulin dose ≤ 0.5 UI/kg/day may include ) , metabolic diseases Renal insufficiency : calculated creatinine clearance le 60 ml/min Acute hepatic disorder ( liver enzymes 50 % upper normal limit ) Chronic hepatitis within last two year ( positive hepatitis titer , Hepatitis A Virus , Hepatitis B Virus , Hepatitis C Virus , cytomegalovirus , EpsteinBarr virus abnormal immunological value ( positive immunoglobulin M ( IgM ) /IgG ) allow liver enzymes within normal range ) Recent history liver disease ( 2 year ) include drug intoxication ( e.g . narcotic , cytostatics etc . ) Patients obvious symptom dehydration History drug alcohol abuse dependence hepatotoxic agent ( patient permanently hospitalise drug screen perform begin hospitalisation , additional drug screen necessary ) Neoplasm currently active likely recur ( except basal cell carcinoma ) Participation another clinical trial within last four week reentering previous talsaclidine trial Pregnant lactate woman , woman childbearing potential use approved method contraception Insufficient compliance : investigator 's opinion patient family unable comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>